Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France.

Loïg Gaugain, Hélène Cawston,Coline Dubois de Gennes, Javier Sanchez Alvares,Pierre Nahon,Benjamin Mazaleyrat, Clément Le Dissez

PloS one（2023）

引用 2|浏览1

暂无评分

摘要

ATZ+BVA is a cost-effective strategy based on the range recently published for the value of a QALY in France and offers better chances of survival to patients.

查看译文

关键词

advanced hepatocellular carcinoma,hepatocellular carcinoma,atezolizumab,bevacizumab,cost-utility

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要